NCT06950788 Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
| NCT ID | NCT06950788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Cirrhosis, Liver |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-12 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-03-12 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant? Participants will be asked to periodically participate in wearing a continuous glucose monitor and wrist actigraph and obtain an oral glucose tolerance test both before and after liver transplant.
Eligibility Criteria
Inclusion Criteria: * Patients presenting to liver transplant clinic with a diagnosis of cirrhosis. * Age \>18 yrs. * Ability to understand and sign written consent form, or have a legally-authorized representative or proxy who can be approached for consent Exclusion Criteria: * Patients without consent * Patients with implantable cardioverter defibrillator devices or automated implantable cardioverter defibrillator devices will be excluded from the bio-electrical impedance analysis portion of the measurements. * Patients with unremovable electrical medical devices or devices that cannot turn off will be excluded from the bio-electrical impedance analysis measurements * Pregnant patients * Incarcerated patients * Patients with a history of type 2 diabetes mellitus diagnosed \> 5 years ago will be excluded from the Oral Glucose Tolerance Test portion of the study
Contact & Investigator
Alan L Hutchison, MD PhD
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06950788 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cirrhosis, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06950788 currently recruiting?
Yes, NCT06950788 is actively recruiting participants. Contact the research team at Alan.Hutchison@uchicagomedicine.org for enrollment information.
Where is the NCT06950788 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06950788 clinical trial?
NCT06950788 is sponsored by University of Chicago. The principal investigator is Alan L Hutchison, MD PhD at University of Chicago. The trial plans to enroll 60 participants.